Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study

Rajesh Narendran · with National Institute on Drug Abuse (NIDA) · NCT07773649

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–45 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
40
US sites recruiting
1
Study start
September 4, 2026
Record last updated
September 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Studies proposed in this application will image mitochondrial Complex-I in cocaine use disorder (CUD) and matched healthy controls

Being studied: [F-18]BCPP-EF

Conditions: Cocaine Use Disorder; Healthy Controls Group - Age and Sex-matched

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Cocaine use disorders (CUD)

  • Males or females between 18 and 45 years old.
  • fulfill DSM-5 criteria for moderate or severe (4+ criteria) cocaine use disorder.
  • No lifetime DSM-5 schizophrenia, schizoaffective disorder, bipolar disorder, and developmental disorders.
  • No comorbid DSM-5 major depressive or severe anxiety disorders (including cocaine-induced mood and anxiety disorders) in the past 12 months.
  • No comorbid DSM-5 alcohol, opioids, sedative-hypnotics, hallucinogens, and inhalant use disorders in the past 12 months. Subjects with a moderate to severe DSM-5 cannabis use disorder will also be excluded.
  • Not currently on psychotropic or medical medications that can influence binding to MC-I (e.g., metformin) or CGM (e.g., insulin, GLP-1 agonists), or increase the risks associated with an arterial line (e.g., warfarin, clopidogrel, aspirin, naproxen, ibuprofen, etc.).
  • No comorbid medical disorders that can influence the PET outcome measures (for example, MC-I binding is altered in Parkinson' disease, mild or major neurocognitive disorders, mitochondrial disorders, immune disorders; and CGM is altered in diabetes, severe hyperlipidemia, hypertension, obesity), or are a contraindication for blood sampling (anemia), or placement of an arterial line (history of deep vein thrombosis, pulmonary embolism, thrombocytopenia or thrombocytosis).
  • Not currently pregnant or breast-feeding.
  • Not currently employed as radiation worker; or has not participated in a radiation-related research protocol within the previous year such that the total cumulative annual radiation dose (i.e., from participation in previous radioactive drug studies and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of radiotracers.
  • No medical or psychiatric contraindications to undergo an MRI scan (such as ferromagnetic tattoos/piercings, implants, medical equipment, history of gunshot, and claustrophobia).

Healthy controls (HC)

  • Males or females between 18 and 45 years old.
  • No DSM-5 psychiatric or substance use disorder other than tobacco use disorder
  • 6 to 10 above.

Recruiting US locations

Study contacts (from the official record)

  • Rajesh Narendran · 412-647-5176 · narendranr@upmc.edu
Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a… (NCT07773649) | Bored Studies